Integra Lifesciences Holdings Corp (IART) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2011

Exhibit 99.1

News Release

Contacts:


Integra LifeSciences Holdings Corporation
John B. Henneman, III		Investor Relations:
Executive Vice President, Chief Financial Officer		Angela Steinway
(609) 275-0500		(609) 936-2268
jack.henneman@integralife.com		angela.steinway@integralife.com

Integra LifeSciences Reports Fourth Quarter and Full-Year 2011 Financial Results

Results In Line with Preliminary Announcement

Provides 2012 Guidance

Plainsboro, New Jersey, February 23, 2012 –

Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the fourth quarter and full year ending December 31, 2011. Total revenues for the fourth quarter were $203.5 million, reflecting an increase of $9.4 million, or 5%, over the fourth quarter of 2010. Total revenues in the full year of 2011 were $780.1 million, reflecting an increase of $48 million, or 7%, over the full year of 2010. Excluding the impact of currency exchange rates, revenues increased 5% over the fourth quarter of 2010 and 5% over the full year 2010. We present revenues by product category in a table at the end of this press release.

The Company reported GAAP net income of $4.6 million, or $0.16 per diluted share, for the fourth quarter of 2011, compared to GAAP net income of $18.8 million, or $0.63 per diluted share, for the fourth quarter of 2010. The Company reported GAAP net income of $28.0 million, or $0.95 per diluted share, for the full year 2011, compared to GAAP net income of $65.7 million, or $2.17 per diluted share in 2010.

Adjusted net income for the fourth quarter of 2011, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $20.6 million, or $0.72 per diluted share, compared to $24.0 million, or $0.80 per diluted share, in the fourth quarter of 2010. Adjusted net income for the full year 2011, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $82.2 million, or $2.79 per diluted share, compared to $89.9 million, or $2.97 per diluted share in 2010.

Integra generated $34.7 million in cash flows from operations and used $13 million of cash on capital expenditures in the fourth quarter of 2011. For the full year ended December 31, 2011, Integra’s cash flows from operations totaled $104.3 million. The Company used $38.4 million of cash on capital expenditures during the year.

The following information was filed by Integra Lifesciences Holdings Corp (IART) on Thursday, February 23, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Integra Lifesciences Holdings Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Integra Lifesciences Holdings Corp.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/917520/000119312512081503/d261286d10k.htm